NASDAQ:DERM

Journey Medical (DERM) Stock Price, News & Analysis

Journey Medical logo
$3.29 -0.26 (-7.32%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$3.34 +0.05 (+1.52%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Journey Medical Stock (NASDAQ:DERM)

Advanced

Key Stats

Today's Range
$3.21
▼
$3.57
50-Day Range
$3.29
▼
$7.38
52-Week Range
$3.21
▼
$9.56
Volume
244,737 shs
Average Volume
216,159 shs
Market Capitalization
$92.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00
Consensus Rating
Hold

Company Overview

Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and marketing prescription treatments for dermatological conditions. Founded in 2014 and based in Scottsdale, Arizona, the company primarily serves the U.S. market.

Its portfolio includes treatments for conditions such as acne, rosacea, excessive underarm sweating and fungal skin infections. Products include Amzeeq and Zilxi, topical minocycline therapies; Qbrexza, a topical treatment for primary axillary hyperhidrosis; and the oral rosacea treatment Emrosi.

Journey Medical markets its products through a U.S. commercial organization and works to expand its dermatology portfolio through product development, licensing and acquisitions.

AI Generated. May Contain Errors.

Journey Medical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
33rd Percentile Overall Score

DERM MarketRank™: 
1.665731912505 of 5 stars

Journey Medical scored higher than 33% of companies evaluated by MarketBeat, and ranked 694th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Journey Medical has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 2 sell ratings.

  • Upside Potential

    Journey Medical has a consensus price target of $13.00, representing about 295.1% upside from its current price of $3.29.

  • Amount of Analyst Coverage

    Journey Medical has only been the subject of 4 research reports in the past 90 days.

  • Read more about Journey Medical's stock forecast and price target.
  • Earnings Growth

    Earnings for Journey Medical are expected to grow in the coming year, from ($0.19) to $0.18 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Journey Medical is -18.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Journey Medical is -18.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Journey Medical has a P/B Ratio of 2.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    12.79% of the float of Journey Medical has been sold short.
  • Short Interest Ratio / Days to Cover

    Journey Medical has a short interest ratio ("days to cover") of 15.07, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Journey Medical has recently increased by 3.25%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Journey Medical does not currently pay a dividend.

  • Dividend Growth

    Journey Medical does not have a long track record of dividend growth.

  • News Sentiment

    Journey Medical has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Journey Medical this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for DERM on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Journey Medical insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    14.53% of the stock of Journey Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    7.25% of the stock of Journey Medical is held by institutions.

  • Read more about Journey Medical's insider trading history.
Receive DERM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Journey Medical and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DERM Stock News Headlines

HC Wainwright Estimates Journey Medical FY2026 Earnings
Journey Medical Corp
Under 3 cents a night
Bill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.tc pixel
FY2027 EPS Forecast for Journey Medical Reduced by Analyst
Journey Medical (DERM) Q3 2026 Earnings Call Transcript
See More Headlines

DERM Stock Analysis - Frequently Asked Questions

Journey Medical's stock was trading at $7.71 at the start of the year. Since then, DERM stock has decreased by 57.3% and is now trading at $3.29.

Journey Medical Corporation (NASDAQ:DERM) released its quarterly earnings data on Thursday, November, 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by $0.03. The business had revenue of $18.97 million for the quarter, compared to analysts' expectations of $20.32 million. Journey Medical had a negative trailing twelve-month return on equity of 16.07% and a negative net margin of 7.34%.
Read the conference call transcript
.

Journey Medical (DERM) raised $39 million in an initial public offering on Friday, November 12th 2021. The company issued 3,520,000 shares at $10.00-$12.00 per share.

Journey Medical's top institutional investors include First Eagle Investment Management LLC (1.71%), Marshall Wace LLP (0.69%), Goldman Sachs Group Inc. (0.30%) and State Street Corp (0.25%). Insiders that own company stock include Claude Maraoui, Ramsey Alloush, Justin Adam Smith and Joseph Benesch.
View institutional ownership trends
.

Shares of DERM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/12/2026
Today
11/22/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:DERM
Previous Symbol
NASDAQ:DERM
CIK
1867066
Fax
N/A
Employees
58
Year Founded
2014

Price Target and Rating

High Price Target
$13.00
Low Price Target
$13.00
Potential Upside/Downside
+295.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.18)
Trailing P/E Ratio
N/A
Forward P/E Ratio
18.28
P/E Growth
N/A
Net Income
-$11.43 million
Net Margins
-7.34%
Pretax Margin
-7.32%
Return on Equity
-16.07%
Return on Assets
-5.26%

Debt

Debt-to-Equity Ratio
0.56
Current Ratio
1.48
Quick Ratio
1.34

Sales & Book Value

Annual Sales
$61.86 million
Price / Sales
1.50
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.14 per share
Price / Book
2.89

Miscellaneous

Outstanding Shares
28,230,000
Free Float
24,129,000
Market Cap
$92.88 million
Optionable
Optionable
Beta
1.14

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:DERM) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners